Immatics Immunotherapy Candidate Shows Confirmed Responses In Different Solid Cancers

  • Immatics N.V. IMTX announced a clinical data update for the IMA203 monotherapy from the Phase 1a dose escalation part of the trial and initial data from the ongoing Phase 1b dose expansion cohort A (monotherapy). 
  • In the Phase 1 trial, IMA203 continues to be well tolerated and achieved confirmed objective responses across multiple solid cancers. 
  • A positively evolving durability profile for IMA203 was observed at higher doses.
  • 6 of 12 patients (50%) treated with more than 1 billion infused TCR-T cells (DL4 and DL5) in the Phase 1a and Phase 1b cohort A part of the trial experienced a confirmed objective response. 
  • In the Phase 1b part of the trial alone, 4 of 5 patients (80%) had a confirmed objective response which was all ongoing at the timepoint of data cut-off.
  • No additional dose-limiting toxicities (DLT) have been observed since the initial data release in March 2021.
  • Further data read-outs on the individual cohorts are planned throughout 2023.
  • Immatics also announced underwritten public offering of 10.9 million shares at $10.09 per share for gross proceeds of approximately $110 million.
  • Price Action: IMTX shares are up 16.10% at $11.72 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFinancingOfferingsSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!